Autolus Therapeutics plc (AUTL)

Current Report Filed: 2026-05-14

Autolus announced Q1 2026 financial results and provided a corporate update on May 14, 2026, indicating ongoing progress in their clinical pipeline and operational status.
The company held a conference call with an updated corporate presentation, suggesting they are actively communicating with investors about strategic developments and financial performance.
As an England and Wales-incorporated biopharmaceutical company trading on Nasdaq, Autolus maintains dual listing status with American Depositary Shares, providing liquidity and accessibility to U.S. investors.

Quarterly Report Filed: 2026-05-14

The filing is dated May 14, 2026 for Q1 2026 (ended March 31, 2026), indicating Autolus Therapeutics is a clinical-stage or commercial-stage biopharmaceutical company with active operations and reporting requirements.
The presence of multiple share classes (Ordinary Shares, Deferred Shares, Class B and Class C Deferred Shares) and ADR members suggests a dual-listing structure, likely London and US exchanges, with complex capital structure that may impact shareholder voting and economic rights.
Detailed tracking of stock-based compensation instruments (RSUs, employee stock options, warrants) across multiple periods indicates significant equity dilution from employee compensation programs, which warrants monitoring for impact on share count and EPS.
The financial instruments disclosed (money market funds, commercial paper, corporate debt, US Treasury securities, foreign government debt) suggest the company maintains substantial cash reserves, though the actual cash balance and burn rate are not visible in the provided metadata.

Current Report Filed: 2026-04-29

Autolus is implementing a 13% workforce reduction with approximately $8 million in restructuring costs, primarily to be recorded in H1 2026, indicating management's focus on operational efficiency amid ongoing business challenges.
The company reaffirmed its 2026 AUCATZYL net product revenue guidance of $120-135 million despite the restructuring, suggesting confidence in the commercial performance of its key therapeutic asset.
The workforce reduction began in H2 2025 and is expected to be completed by Q3 2026, indicating a phased approach to cost reduction that aims to minimize operational disruption while improving financial sustainability.
The 8-K includes extensive forward-looking statement disclaimers and risk acknowledgments, noting that actual implementation results may differ materially from current plans, reflecting uncertainty around execution and potential for additional unforeseen costs.

Current Report Filed: 2026-04-16

Autolus Therapeutics plc has dismissed its independent registered public accounting firm, Ernst & Young LLP (UK), and appointed Ernst & Young LLP (US) as the new auditor effective for the fiscal year ending December 31, 2026.
The company's previous audit reports did not contain any adverse opinions or disclaimers, but there were material weaknesses in the company's internal control over financial reporting as of March 31, 2024.
The company did not consult the new auditor, Ernst & Young LLP (US), on any significant accounting or auditing matters during the prior two fiscal years.

Current Report Filed: 2026-04-08

Autolus Therapeutics plc hosted a virtual investor event focused on its Acute Lymphoblastic Leukemia (ALL) business, providing insights into its product pipeline and clinical development progress.
The presentation materials attached to the 8-K filing indicate that Autolus is making advancements in its ALL treatments, which could be of interest to investors.
The filing does not provide any financial updates or guidance, so the significance is primarily around the company's operational and pipeline developments.

Current Report Filed: 2026-03-27

Autolus Therapeutics reported its full year 2025 financial results, providing investors with an update on the company's operations and progress.
The company's corporate presentation indicates it is continuing to advance its pipeline of cell therapy candidates, which could be of interest to investors tracking its R&D developments.
The 8-K filing and accompanying materials do not appear to indicate any major unexpected events or changes, suggesting a relatively routine quarterly update for the company.

Annual Report Filed: 2026-03-27

Autolus Therapeutics reported a 15% year-over-year increase in product revenue, indicating strong demand for its therapies.
The company's operating expenses grew by 25% due to increased R&D and manufacturing costs, which may impact profitability in the short term.
Autolus signed a strategic collaboration and financing agreement with BioNTech, potentially unlocking additional revenue streams and advancing its pipeline.

Current Report Filed: 2026-01-26

Autolus Therapeutics plc has entered into a 10-year Master Service Agreement with AGC Biologics S.p.A. for the manufacture and supply of lentiviral vector, a critical raw material for the company's CAR-T product pipeline.
The agreement includes commitments for Autolus to purchase a minimum of 14 batches of lentiviral vector in the first two years and a minimum of EUR 25 million in products and services over the subsequent five-year period.
The agreement also provides AGC with the first right to negotiate with Autolus regarding the provision of new manufacturing activities related to Autolus' obe-cel product.

Current Report Filed: 2026-01-12

Autolus Therapeutics announced preliminary unaudited net product revenue from sales of AUCATZYL (obe-cel) of $24 million for Q4 2025 and $75 million for the full year 2025, indicating strong commercial performance.
The company expects its current and projected cash, cash equivalents and marketable securities will be sufficient to fund operations into Q4 2027, providing a favorable cash runway outlook.
Autolus provided guidance for full year 2026 AUCATZYL net product revenue of $120 million to $135 million, suggesting continued growth expectations for the product.
The company highlighted the therapeutic potential and expected clinical benefits of AUCATZYL (obe-cel) for adult patients with r/r B-ALL and in additional indications like lupus nephritis and progressive multiple sclerosis, indicating pipeline expansion opportunities.

Important Information